Expanded Access Program for Mezigdomide: Information for Patients and Families

What is this expanded access program about?

Bristol-Myers Squibb is offering an expanded access program (sometimes called 'compassionate use') for an investigational drug called Mezigdomide. This program allows patients who cannot participate in clinical trials to potentially access treatments that are not yet approved by the FDA.

Who might qualify for this program?

The program is open to children, adults, and older adults. Since this is an expanded access program rather than a clinical trial, there are no healthy volunteers involved. The exact eligibility criteria haven't been specified yet, which means doctors would need to contact Bristol-Myers Squibb directly to discuss whether a particular patient might qualify.

What is Mezigdomide?

Mezigdomide is an experimental medication currently being studied for various medical conditions. While we can't provide specific details about its uses in this program (as that information would come from your healthcare team), expanded access programs like this one are typically for serious conditions where existing treatments aren't working.

How does expanded access work?

Expanded access programs are important because they:

• Provide possible treatment options when no alternatives exist
• Allow patients who can't join clinical trials to access investigational drugs
• Help researchers learn more about how treatments work in different patients

Why is this research important?

Expanded access programs play a crucial role in medical research and patient care. They represent a balance between making promising treatments available while still collecting important safety data. For many families facing serious illnesses, these programs offer hope when other options have been exhausted.

How to learn more or apply?

The first step is to have your doctor contact the BMS Clinical Trials Contact Center. The email must include the NCT number and Site number (which your healthcare provider can help with). More information is available at www.BMSClinicalTrials.com.

Considerations for patients and families:

While expanded access offers potential benefits, it's important to understand that investigational drugs may have unknown side effects or may not work as hoped. Your medical team can help you weigh the potential benefits against the risks. Remember that participation is completely voluntary, and you can stop at any time.

The field of expanded access is growing as researchers and pharmaceutical companies recognize the importance of making experimental treatments available outside of traditional clinical trials. This reflects a broader commitment to patient-centered care and recognizing the urgent needs of those with serious health conditions.

For caregivers, it's important to know that expanded access programs often require significant documentation and coordination with healthcare providers. The process may take time, so it's best to start conversations early if you're considering this path.

Medical research continues to evolve, with expanded access programs becoming more common for serious conditions where the potential benefits outweigh the risks. These programs represent hope for many patients and contribute valuable information to the scientific community about how new treatments work in diverse patient populations.